TMCnet News
Piper Jaffray Expands Healthcare Equity Research with the Hiring of Tyler Van BurenPiper Jaffray Companies (NYSE: PJC), a leading investment bank and asset management firm, is pleased to announce the hiring of Tyler Van Buren as a senior research analyst responsible for covering biotechnology companies. He will be based in the firm's New York office. In 2017, Institutional Investor recognized Van Buren as the No. 1 Rising Star in the specialty pharma category and the No. 2 Rising Star across therapeutics. He joins Piper Jaffray from Cowen and Company, where he was an equity research analyst covering large and smid-cap biopharma companies for five years. Prior to that, Van Buren was a founding member and managing director at New York-based LifeSci Advisors, where he helped build the firm's biotechnology research practice. Earlier in his career, he worked at Amylin Pharmaceuticals, Lithera Pharmaceuticals, the Sanford-Burnham Medical Research Institute and the U.S. Department of Agriculture. "Tyler brings a breadth of both industry and sell-side experience across biopharma, biotech and the broader healthcare space. This addition will add strength to our firm's overall leadership in the healthcare sector and add immediate value for our clients," said Michael Cox, director of equity research at Piper Jaffray. Van Buren earned a master's degree in biology and a bachelor's degree in biochemistry and cellular biology from the University of California, San Diego. The Piper Jaffray equity research group consists of 40 senior analysts covering 680 companies across the following sectors: consumer, energy, financial services, healthcare, industrials & business services, and technology.
About Piper Jaffray Follow Piper Jaffray: LinkedIn | Facebook | Twitter © 2018 Piper Jaffray Companies, 800 Nicollet Mall, Suite 1000, Minneapolis, Minnesota 55402-7036
View source version on businesswire.com: http://www.businesswire.com/news/home/20180123006575/en/ |